DataVXJournal of Nanoparticle ResearchPaper
journal article·2024-06

Development and characterization of temozolomide-PAMAM-siRNA dendriplexes for the effective management of glioblastoma multiforme

Tanisha Gupta, Rakesh Kumar Sahoo, Awesh Kumar Yadav, Umesh Gupta

Journal of Nanoparticle Research· Volume 26· Issue 6
Publisher page
Bibliographic record

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Dendrimers and Hyperbranched Polymers · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (53)

Show source-provided references
1. Abdul Ghafoor Raja M, Katas H, Jing Wen T et al (2015) Stability, Intracellular Delivery, and Release of siRNA from Chitosan Nanoparticles Using Different Cross-Linkers. PLoS One 10:e0128963. https://doi.org/10.1371/JOURNAL.PONE.012896310.1371/JOURNAL.PONE.0128963 ↗
2. Abedi-Gaballu F, Dehghan G, Ghaffari M et al (2018) PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. Appl Mater Today 12:177–190. https://doi.org/10.1016/J.APMT.2018.05.00210.1016/J.APMT.2018.05.002 ↗
3. Ananta JS, Paulmurugan R, Massoud TF (2015) Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells. Mol Pharm 12:4509–4517. https://doi.org/10.1021/acs.molpharmaceut.5b0069410.1021/acs.molpharmaceut.5b00694 ↗
4. Anjum K, Shagufta BI, Abbas SQ et al (2017) Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review. Biomed Pharmacother 92:681–689. https://doi.org/10.1016/J.BIOPHA.2017.05.12510.1016/J.BIOPHA.2017.05.125 ↗
5. Banstola A, Duwa R, Emami F et al (2020) Enhanced caspase-mediated abrogation of autophagy by temozolomide-loaded and panitumumab-conjugated poly(lactic- co-glycolic acid) nanoparticles in epidermal growth factor receptor overexpressing glioblastoma cells. Mol Pharm 17:4386–4400. https://doi.org/10.1021/acs.molpharmaceut.0c0085610.1021/acs.molpharmaceut.0c00856 ↗
6. Bäumer N, Tiemann J, Scheller A et al (2022) Targeted siRNA nanocarrier: a platform technology for cancer treatment. Oncogene 41:2210–2224. https://doi.org/10.1038/s41388-022-02241-w10.1038/s41388-022-02241-w ↗
7. Bulbake U, Kommineni N, Bryszewska M, Ionov M, Khan W (2018) Cationic liposomes for co-delivery of paclitaxel and anti-Plk1 siRNA to achieve enhanced efficacy in breast cancer. J Drug Delivery Sci Technol 48:253–26510.1016/j.jddst.2018.09.017 ↗
8. Dzmitruk V, Apartsin E, Ihnatsyeu-Kachan A et al (2018) Dendrimers Show Promise for siRNA and microRNA Therapeutics. Pharmaceutics 10:126. https://doi.org/10.3390/PHARMACEUTICS1003012610.3390/PHARMACEUTICS10030126 ↗
9. Esfand R, Tomalia DA (2001) Poly(amidoamine) (PAMAM) dendrimers: From biomimicry to drug delivery and biomedical applications. Drug Discov Today 6:427–436. https://doi.org/10.1016/S1359-6446(01)01757-310.1016/S1359-6446(01)01757-3 ↗
10. Florendo M, Figacz A, Srinageshwar B et al (2018) Use of Polyamidoamine Dendrimers in Brain Diseases. Molecules 23:2238. https://doi.org/10.3390/MOLECULES2309223810.3390/MOLECULES23092238 ↗
11. Ghaffari M, Dehghan G, Baradaran B et al (2020) Co-delivery of curcumin and Bcl-2 siRNA by PAMAM dendrimers for enhancement of the therapeutic efficacy in HeLa cancer cells. Colloids Surf B Biointerfaces 188:110762. https://doi.org/10.1016/J.COLSURFB.2019.11076210.1016/J.COLSURFB.2019.110762 ↗
12. Gutkin A, Cohen ZR, Peer D (2016) Harnessing nanomedicine for therapeutic intervention in glioblastoma. Expert Opin Drug Deliv 13:1573–1582. https://doi.org/10.1080/17425247.2016.120055710.1080/17425247.2016.1200557 ↗
13. Imiela A, Surmacki J, Abramczyk H (2020) Novel strategies of Raman imaging for monitoring the therapeutic benefit of temozolomide in glioblastoma. J Mol Struct 1217:128381. https://doi.org/10.1016/J.MOLSTRUC.2020.12838110.1016/J.MOLSTRUC.2020.128381 ↗
14. Ivaturi R, Manikya Sastry T, Satyaveni S (2018) A Stability Indicating UPLC Method for Determination of Temozolomide and its Related Substances in Bulk and Finished Dosage Forms. Asian J Chem 30:1971–1977. https://doi.org/10.14233/AJCHEM.2018.2134810.14233/AJCHEM.2018.21348 ↗
15. Jatyan R, Singh P, Sahel DK et al (2022) Polymeric and small molecule-conjugates of temozolomide as improved therapeutic agents for glioblastoma multiforme. J Control Release 350:494–513. https://doi.org/10.1016/J.JCONREL.2022.08.02410.1016/J.JCONREL.2022.08.024 ↗
16. Jensen LB, Pavan GM, Kasimova MR et al (2011) Elucidating the molecular mechanism of PAMAM–siRNA dendriplex self-assembly: Effect of dendrimer charge density. Int J Pharm 416:410–418. https://doi.org/10.1016/J.IJPHARM.2011.03.01510.1016/J.IJPHARM.2011.03.015 ↗
17. Kang H, DeLong R, Fisher MH, Juliano RL (2005) Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm Res 22:2099–2106. https://doi.org/10.1007/S11095-005-8330-5/FIGURES/710.1007/S11095-005-8330-5/FIGURES/7 ↗
18. Kesharwani P, Banerjee S, Gupta U et al (2015) PAMAM dendrimers as promising nanocarriers for RNAi therapeutics. Mater Today 18:565–572. https://doi.org/10.1016/J.MATTOD.2015.06.00310.1016/J.MATTOD.2015.06.003 ↗
19. Kulothungan V, Sathishkumar K, Leburu S et al (2022) Burden of cancers in India - estimates of cancer crude incidence, YLLs, YLDs and DALYs for 2021 and 2025 based on National Cancer Registry Program. BMC Cancer 22:1–12. https://doi.org/10.1186/S12885-022-09578-110.1186/S12885-022-09578-1 ↗
20. Li J, Chen L, Liu N et al (2016) EGF-coated nano-dendriplexes for tumor-targeted nucleic acid delivery in vivo. Drug Deliv 23:1718–1725. https://doi.org/10.3109/10717544.2015.100438110.3109/10717544.2015.1004381 ↗
21. Li X, Ta W, Hua R et al (2022) A Review on Increasing the Targeting of PAMAM as Carriers in Glioma Therapy. Biomedicines 10:2455. https://doi.org/10.3390/BIOMEDICINES1010245510.3390/BIOMEDICINES10102455 ↗
22. Liu C, Liu X, Rocchi P et al (2014) Arginine-terminated generation 4 PAMAM dendrimer as an effective nanovector for functional siRNA delivery in vitro and in vivo. Bioconjug Chem 25:521–532. https://doi.org/10.1021/BC400515610.1021/BC4005156 ↗
23. Liu Z, Wang T, Zhang Z et al (2017) Survivin downregulation using siRNA nanoliposomes inhibits cell proliferation and promotes the apoptosis of MHCC-97H hepatic cancer cells: An in vitro and in vivo study. Oncol Lett 13:2723–2730. https://doi.org/10.3892/OL.2017.5754/HTML10.3892/OL.2017.5754/HTML ↗
24. Liyanage W, Wu T, Kannan S, Kannan RM (2022) Dendrimer-siRNA Conjugates for Targeted Intracellular Delivery in Glioblastoma Animal Models. ACS Appl Mater Interfaces 14:46290–46303. https://doi.org/10.1021/ACSAMI.2C13129/SUPPL_FILE/AM2C13129_SI_001.PDF10.1021/ACSAMI.2C13129/SUPPL_FILE/AM2C13129_SI_001.PDF ↗
25. Lopes IC, De Oliveira SCB, Oliveira-Brett AM (2013) Temozolomide chemical degradation to 5-aminoimidazole-4-carboxamide – Electrochemical study. J Electroanal Chem 704:183–189. https://doi.org/10.1016/J.JELECHEM.2013.07.01110.1016/J.JELECHEM.2013.07.011 ↗
26. Lucas P, Milroy DA, Thomas BJ et al (1999) Pharmaceutical and Biological Properties of Poly(amino acid)/DNA Polyplexes. J Drug Target 7:143–156. https://doi.org/10.3109/1061186990908549810.3109/10611869909085498 ↗
27. Maiti PK, Çaǧin T, Wang G, Goddard WA (2004) Structure of PAMAM dendrimers: Generations 1 through 11. Macromolecules 37:6236–6254. https://doi.org/10.1021/MA035629B/SUPPL_FILE/MA035629BSI20040618_12585110.1021/MA035629B/SUPPL_FILE/MA035629BSI20040618_125851 ↗
28. Marson D, Laurini E, Aulic S et al (2019) Evolution from Covalent to Self-Assembled PAMAM-Based Dendrimers as Nanovectors for siRNA Delivery in Cancer by Coupled In Silico-Experimental Studies. Part I: Covalent siRNA Nanocarriers. Pharmaceutics 11:351. https://doi.org/10.3390/PHARMACEUTICS1107035110.3390/PHARMACEUTICS11070351 ↗
29. Mendes LP, Pan J, Torchilin VP (2017) Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy. Molecules 22:1401. https://doi.org/10.3390/MOLECULES2209140110.3390/MOLECULES22091401 ↗
30. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63. https://doi.org/10.1016/0022-1759(83)90303-410.1016/0022-1759(83)90303-4 ↗
31. Newlands ES, Stevens MFG, Wedge SR et al (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35–61. https://doi.org/10.1016/S0305-7372(97)90019-010.1016/S0305-7372(97)90019-0 ↗
32. Pandi P, Jain A, Kommineni N et al (2018) Dendrimer as a new potential carrier for topical delivery of siRNA: A comparative study of dendriplex vs. lipoplex for delivery of TNF-α siRNA. Int J Pharm 550:240–250. https://doi.org/10.1016/J.IJPHARM.2018.08.02410.1016/J.IJPHARM.2018.08.024 ↗
33. Perez AP, Cosaka ML, Romero L et al (2011) Uptake and intracellular traffic of siRNA dendriplexes in glioblastoma cells and macrophages. Int J Nanomedicine 6:2730. https://doi.org/10.2147/IJN.S2523510.2147/IJN.S25235 ↗
34. Perez AP, Romero EL, Morilla MJ (2009) Ethylendiamine core PAMAM dendrimers/siRNA complexes as in vitro silencing agents. Int J Pharm 380:189–200. https://doi.org/10.1016/J.IJPHARM.2009.06.03510.1016/J.IJPHARM.2009.06.035 ↗
35. Prather KY, O’Neal CM, Westrup AM et al (2022) A systematic review of amino acid PET in assessing treatment response to temozolomide in glioma. Neuro-Oncology Adv 4. https://doi.org/10.1093/NOAJNL/VDAC00810.1093/NOAJNL/VDAC008 ↗
36. Qiu J, Kong L, Cao X et al (2018) Enhanced delivery of therapeutic siRNA into glioblastoma cells using dendrimer-entrapped gold nanoparticles conjugated with β-cyclodextrin. Nanomaterials 8:01–13. https://doi.org/10.3390/NANO803013110.3390/NANO8030131 ↗
37. Sadekar S, Ghandehari H (2012) Transepithelial transport and toxicity of PAMAM dendrimers: Implications for oral drug delivery. Adv Drug Deliv Rev 64:571–588. https://doi.org/10.1016/J.ADDR.2011.09.01010.1016/J.ADDR.2011.09.010 ↗
38. Sahoo RK, Gothwal A, Rani S et al (2020) PEGylated Dendrimer Mediated Delivery of Bortezomib: Drug Conjugation versus Encapsulation. Int J Pharm 584:119389. https://doi.org/10.1016/J.IJPHARM.2020.11938910.1016/J.IJPHARM.2020.119389 ↗
39. Sawicki T, Ruszkowska M, Danielewicz A et al (2021) A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis. Cancers (Basel) 13:2025. https://doi.org/10.3390/CANCERS1309202510.3390/CANCERS13092025 ↗
40. Senturk F, Cakmak S, Gumusderelioglu M, Ozturk GG (2022) Hydrolytic instability and low-loading levels of temozolomide to magnetic PLGA nanoparticles remain challenging against glioblastoma therapy. J Drug Deliv Sci Technol 68:103101. https://doi.org/10.1016/J.JDDST.2022.10310110.1016/J.JDDST.2022.103101 ↗
41. Sharma AK, Gupta L, Gupta U (2017) Nanoparticles as nucleic acid delivery vectors. Adv Nanomed Deliv Ther Nucleic Acids:13–42. https://doi.org/10.1016/B978-0-08-100557-6.00002-X10.1016/B978-0-08-100557-6.00002-X ↗
42. Sharma AK, Gupta L, Sahu H et al (2018) Chitosan engineered PAMAM dendrimers as nanoconstructs for the enhanced anti-cancer potential and improved in vivo brain pharmacokinetics of temozolomide. Pharm Res 35:1–14. https://doi.org/10.1007/S11095-017-2324-Y/TABLES/510.1007/S11095-017-2324-Y/TABLES/5 ↗
43. Singh A, Id C (2018) Dendrimers for Drug Delivery. Molecules 23:938. https://doi.org/10.3390/MOLECULES2304093810.3390/MOLECULES23040938 ↗
44. Singh P, Gupta U, Asthana A, Jain NK (2008) Folate and folate-PEG-PAMAM dendrimers: Synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug Chem 19:2239–2252. https://doi.org/10.1021/BC800125U/SUPPL_FILE/BC800125U_SI_001.PDF10.1021/BC800125U/SUPPL_FILE/BC800125U_SI_001.PDF ↗
45. Slowing II, Wu CW, Vivero-Escoto JL, Lin VSY (2009) Mesoporous Silica Nanoparticles for Reducing Hemolytic Activity Towards Mammalian Red Blood Cells. Small 5:57–62. https://doi.org/10.1002/SMLL.20080092610.1002/SMLL.200800926 ↗
46. Surekha B, Kommana NS, Dubey SK et al (2021) PAMAM dendrimer as a talented multifunctional biomimetic nanocarrier for cancer diagnosis and therapy. Colloids Surf B Biointerfaces 204:111837. https://doi.org/10.1016/J.COLSURFB.2021.11183710.1016/J.COLSURFB.2021.111837 ↗
47. Tan SJ, Kiatwuthinon P, Roh YH et al (2011) Engineering Nanocarriers for siRNA Delivery. Small 7:841–856. https://doi.org/10.1002/SMLL.20100138910.1002/SMLL.201001389 ↗
48. Temozolomide: Uses, Interactions, Mechanism of Action | DrugBank Online. https://go.drugbank.com/drugs/DB00853. Accessed 3 Oct 2023
49. Thomas A, Tanaka M, Trepel J et al (2017) Temozolomide in the era of precision medicine. Cancer Res 77:823–826. https://doi.org/10.1158/0008-5472.CAN-16-2983/66093910.1158/0008-5472.CAN-16-2983/660939 ↗
50. Tomalia DA, Baker H, Dewald J et al (1985) A new class of polymers: Starburst-dendritic macromolecules. Polym J 17:117–132. https://doi.org/10.1295/polymj.17.11710.1295/polymj.17.117 ↗
51. Tomalia DA, Fréchet JMJ (2002) Discovery of dendrimers and dendritic polymers: A brief historical perspective*. J Polym Sci Part A Polym Chem 40:2719–2728. https://doi.org/10.1002/POLA.1030110.1002/POLA.10301 ↗
52. Voytas D (2000) Agarose Gel Electrophoresis. Curr Protoc Mol Biol 51:2.5A.1–2.5A.9. https://doi.org/10.1002/0471142727.MB0205AS5110.1002/0471142727.MB0205AS51 ↗
53. Zhang Z, Wang T, Liu Z et al (2017) Small interfering RNA targeting of the survivin gene inhibits human tumor cell growth in vitro. Exp Ther Med 14:35–42. https://doi.org/10.3892/ETM.2017.4501/HTML10.3892/ETM.2017.4501/HTML ↗